The Lancet: World's First! AI Breaks Through Ferti
2025-11-11
Page Views：719
In global infertility cases, male factors account for up to 40%, among which azoospermia and cryptozoospermia account for approximately 10%-15% of male infertility cases. For couples affected by this, years of repeated invasive treatments and lengthy manual sperm searches often end in failure, forcing them to face the choice of donor sperm or adoption.
On October 31, 2025, researchers from Columbia University Medical Center published a study titled "First clinical pregnancy following AI-based microfluidic sperm detection and recovery in non-obstructive azoospermia" in the international top medical journal The Lancet.
The Sperm Tracking and Recovery (STAR) system developed in this study has brought revolutionary changes, successfully achieving the world's first clinical pregnancy and opening up a new fertility path for patients with severe male factor infertility.
The STAR System: Innovative Integration of AI and Microfluidics
The STAR system is a fully automated, non-invasive sperm detection and recovery platform. Its core consists of three major components that work together to achieve efficient and accurate sperm identification and separation. Firstly, a high-speed imaging system capable of continuously capturing phase-contrast images at 300 frames per second. Secondly, a custom-designed Fusion DTx microfluidic chip that provides a precise microenvironment for sperm separation. Finally, a deep learning-based object detection model adopting the YOLO architecture, specifically trained and optimized with annotated sperm images.
The system's operational efficiency is impressive: it can analyze 400 microliters of semen samples per hour, with an image capture and processing rate of 1.1 million images per hour. To ensure detection accuracy, the research team added a temporal consistency filter—only when a target is identified at least 3 times in approximately 10 consecutive frames is it confirmed as a sperm.
Once sperm are identified, a microfluidic gating mechanism separates them into a volume of 300 nanoliters. All fluidic components are disposable, ensuring sterility and eliminating the risk of cross-contamination. The entire system operates in a closed manner to maximize biosafety. In validation experiments, when a known number of sperm (5-100 per 400 microliters) were added to azoospermic samples, the STAR system's detection results showed an extremely high linear correlation with the actual number of added sperm (R²=0.99), with a detection precision of 0.89, recall of 0.90, and mean average precision of 0.95 at an intersection over union of 0.5—fully demonstrating its detection reliability.
Breaking the 20-Year Infertility Dilemma: First Successful Clinical Pregnancy
The first clinical application of the system was on a couple who had suffered from infertility for 19 years. The 39-year-old male patient underwent a comprehensive reproductive urological evaluation, showing a normal karyotype, no Y-chromosome microdeletions, and normal serum testosterone and follicle-stimulating hormone levels. However, scrotal ultrasound revealed bilateral testicular atrophy with microlithiasis and no signs of varicocele. He had previously undergone multiple large-scale manual sperm searches and two testicular sperm extraction surgeries, recovering only a small number of rare sperm. The 37-year-old female patient had severe diminished ovarian reserve with an anti-Müllerian hormone level of only 0.17 ng/mL. Over the past 11 years, she had undergone 19 oocyte retrieval cycles at 4 reproductive centers, including multiple oocyte cryopreservation due to insufficient sperm. Intracytoplasmic sperm injection (ICSI) attempted in some cycles failed due to low fertilization rates, resulting in only 1 transferable embryo that did not lead to pregnancy.
During treatment, the research team gently washed a 3.5-milliliter ejaculated semen sample, resuspended it in 800 microliters of semen analysis buffer, and processed it with the STAR system. No sperm were found in manual smear examinations, but the STAR system analyzed 2.5 million images in approximately 2 hours, successfully detecting 7 sperm—2 motile and 5 non-motile.
Doctors injected the motile sperm into 2 mature oocytes (1 freshly retrieved and 1 thawed), both of which developed into cleavage-stage embryos; the other 2 thawed oocytes injected with non-motile sperm did not continue to develop. On day 3, the two embryos were successfully transferred. Thirteen days after transfer, the patient obtained the first positive pregnancy result, which was ultimately confirmed as a clinical pregnancy. At 8 weeks of gestation, ultrasound examination showed normal fetal development with a heart rate of 172 beats per minute, and the patient has been transferred to obstetric care.
Technological Innovation: Rewriting the Treatment Landscape for Severe Male Infertility
Traditional sperm recovery methods for azoospermia and cryptozoospermia often rely on invasive surgery or long-term manual searches by embryologists, which are not only time-consuming and labor-intensive with low success rates but also highly influenced by the operator's experience.
In contrast, the STAR system combines real-time AI technology with precise microfluidic technology to achieve non-invasive, automated identification and recovery of rare sperm, completely changing this situation. Although the STAR system has previously successfully recovered and cryopreserved sperm in other azoospermic patients, this case marks the first time that recovered sperm have been directly used for fertilization leading to clinical pregnancy, and it is also the world's first clinical pregnancy achieved through sperm identified and recovered by an AI-guided microfluidic platform.
Despite being based on a single case, this breakthrough fully demonstrates the feasibility of the technology and brings new hope to patients with severe male factor infertility who have long faced treatment difficulties. Currently, larger-scale clinical studies are underway to evaluate the reproducibility, effectiveness, and treatment outcomes of the technology in a broader patient population. The successful application of the STAR system highlights the transformative potential of AI-guided microfluidic technology in reproductive medicine, which is expected to further expand the boundaries of fertility care and restore fertility hope to more infertile patients once deemed "untreatable."
